It is suggested that Nox4 facilitates tumor lymphangiogenesis via the ROS/ERK/CCL21 pathway, thereby drawing CCR7-positive breast cancer cells towards lymphatic channels and distant anatomical sites.123 Sunitinib is a receptor tyrosine kinase (RTK) inhibitor that targets many receptors, including vascular endothelial growth factor receptors (VEGFRs). This evidence concerns the gene NOX4 and neoplasm.